VA SB274 | 2024 | Regular Session

Status

Spectrum: Moderate Partisan Bill (Democrat 8-1)
Status: Vetoed on April 8 2024 - 100% progression
Action: 2024-04-17 - Senate sustained Governor's veto
Text: Latest bill text (Enrolled) [HTML]

Summary

Prescription Drug Affordability Board established; drug cost affordability review. Establishes the Prescription Drug Affordability Board for the purpose of protecting the citizens of the Commonwealth and other stakeholders within the health care system from the high costs of prescription drug products. The bill requires the Board to meet in open session at least four times annually, with certain exceptions and requirements enumerated in the bill. Members of the Board are required to disclose any conflicts of interest, as described in the bill. The bill also creates a stakeholder council for the purpose of assisting the Board in making decisions related to drug cost affordability. The bill tasks the Board with identifying prescription, generic, and other drugs, as defined in the bill, that are offered for sale in the Commonwealth and, at the Board's discretion, conducting an affordability review of any prescription drug product. The bill lists factors for the Board to consider that indicate an affordability challenge for the health care system in the Commonwealth or high out-of-pocket costs for patients. The bill also provides that any person aggrieved by a decision of the Board may request an appeal of the Board's decision and that the Attorney General has authority to enforce the provisions of the bill. The bill provides that the Board shall establish no more than 12 upper payment limit amounts annually between January 1, 2025, and January 1, 2028. Prescription Drug Affordability Board established; drug cost affordability review. Establishes the Prescription Drug Affordability Board for the purpose of protecting the citizens of the Commonwealth and other stakeholders within the health care system from the high costs of prescription drug products. The bill requires the Board to meet in open session at least four times annually, with certain exceptions and requirements enumerated in the bill. Members of the Board are required to disclose any conflicts of interest, as described in the bill. The bill also creates a stakeholder council for the purpose of assisting the Board in making decisions related to drug cost affordability. The bill tasks the Board with identifying prescription, generic, and other drugs, as defined in the bill, that are offered for sale in the Commonwealth and, at the Board's discretion, conducting an affordability review of any prescription drug product. The bill lists factors for the Board to consider that indicate an affordability challenge for the health care system in the Commonwealth or high out-of-pocket costs for patients. The bill also provides that any person aggrieved by a decision of the Board may request an appeal of the Board's decision and that the Attorney General has authority to enforce the provisions of the bill. The bill provides that the Board shall establish no more than 12 upper payment limit amounts annually between January 1, 2025, and January 1, 2028. The bill requires the Board to report its findings and recommendations to the General Assembly twice annually, beginning on July 1, 2025, and December 31, 2025. Provisions of the bill shall apply to state-sponsored and state-regulated health plans and health programs and obligate such policies to limit drug payment amounts and reimbursements to an upper payment limit amount set by the Board, if applicable, following an affordability review. The bill specifies that Medicare Part D plans shall not be bound by such decisions of the Board. The bill also requires the nonprofit organization contracted by the Department of Health to provide prescription drug price transparency to provide the Board access to certain data reported by manufacturers. The bill has a delayed effective date of January 1, 2025, and is identical to

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Prescription Drug Affordability Board; established, drug cost affordability review, report.

Sponsors


Roll Calls

2024-04-17 - Senate - Senate: Passed in enrolled form rejected (21-Y 18-N) (Y: 21 N: 18 NV: 0 Abs: 1) [PASS]
2024-02-23 - House - House: VOTE: Passage (50-Y 47-N) (Y: 50 N: 47 NV: 0 Abs: 3) [PASS]
2024-02-20 - House - House: Reported from Labor and Commerce (12-Y 10-N) (Y: 12 N: 10 NV: 0 Abs: 0) [PASS]
2024-02-13 - Senate - Senate: Read third time and passed Senate (23-Y 16-N) (Y: 23 N: 16 NV: 0 Abs: 1) [PASS]
2024-02-09 - Senate - Senate: Constitutional reading dispensed (39-Y 0-N) (Y: 39 N: 0 NV: 0 Abs: 1) [PASS]
2024-02-08 - Senate - Senate: Reported from Finance and Appropriations (9-Y 6-N) (Y: 9 N: 6 NV: 0 Abs: 0) [PASS]
2024-02-05 - Senate - Senate: Reported from Commerce and Labor with substitute (10-Y 5-N) (Y: 10 N: 5 NV: 0 Abs: 0) [PASS]
2024-01-18 - Senate - Senate: Rereferred from Education and Health (15-Y 0-N) (Y: 15 N: 0 NV: 0 Abs: 0) [PASS]

History

DateChamberAction
2024-04-17SenateSenate sustained Governor's veto
2024-04-17SenateRequires 2/3 members present
2024-04-17SenatePassed in enrolled form rejected (21-Y 18-N)
2024-04-08 Governor: Vetoed by Governor
2024-03-11 Governor: Governor's Action Deadline 11:59 p.m., April 8, 2024
2024-03-11SenateEnrolled Bill Communicated to Governor on March 11, 2024
2024-03-02SenateSigned by President
2024-02-28HouseSigned by Speaker
2024-02-28SenateBill text as passed Senate and House (SB274ER)
2024-02-28SenateEnrolled
2024-02-23HouseVOTE: Passage (50-Y 47-N)
2024-02-23HousePassed House (50-Y 47-N)
2024-02-23HouseRead third time
2024-02-22HouseRead second time
2024-02-20HouseReported from Labor and Commerce (12-Y 10-N)
2024-02-15HouseReferred to Committee on Labor and Commerce
2024-02-15HouseRead first time
2024-02-15HousePlaced on Calendar
2024-02-13SenateRead third time and passed Senate (23-Y 16-N)
2024-02-12SenateEngrossed by Senate - committee substitute SB274S1
2024-02-12SenateCommittee substitute agreed to 24106998D-S1
2024-02-12SenateReading of substitute waived
2024-02-12SenateRead second time
2024-02-09SenateConstitutional reading dispensed (39-Y 0-N)
2024-02-08SenateReported from Finance and Appropriations (9-Y 6-N)
2024-02-05SenateRereferred to Finance and Appropriations
2024-02-05SenateSubstitute bill reprinted 24106998D-S1
2024-02-05SenateCommittee substitute printed 24106998D-S1
2024-02-05SenateReported from Commerce and Labor with substitute (10-Y 5-N)
2024-01-18SenateRereferred to Commerce and Labor
2024-01-18SenateRereferred from Education and Health (15-Y 0-N)
2024-01-09SenateReferred to Committee on Education and Health
2024-01-09SenatePrefiled and ordered printed; offered 01/10/24 24101144D

Same As/Similar To

HB570 (Similar To) 2024-04-17 - House sustained Governor's veto

Subjects


Code Citations

ChapterArticleSectionCitation TypeStatute Text
321276.12(n/a)See Bill Text
321276.21(n/a)See Bill Text
5413442.02(n/a)See Bill Text

Virginia State Sources

TypeSource
Summaryhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+sum+SB274
Texthttps://lis.virginia.gov/cgi-bin/legp604.exe?241+ful+SB274+hil
Texthttps://lis.virginia.gov/cgi-bin/legp604.exe?241+ful+SB274S1+hil
Texthttps://lis.virginia.gov/cgi-bin/legp604.exe?241+ful+SB274ER+hil
Amendmenthttps://committees.lis.virginia.gov/pdfs/drafts/24106998D.pdf
Amendmenthttps://lis.virginia.gov/cgi-bin/legp604.exe?241+amd+SB274AG
Supplementhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+oth+SB274F122+PDF
Supplementhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+oth+SB274FS1122+PDF
Supplementhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+oth+SB274FER122+PDF
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+vot+S04V0009+SB0274
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+vot+S02V0054+SB0274
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+vot+S05V0265+SB0274
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+vot+SV0328SB0274+SB0274
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+vot+SV0405SB0274+SB0274
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+vot+H14V0170+SB0274
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+vot+HV1117+SB0274
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+vot+SV1289SB0274+SB0274

Bill Comments

feedback